Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma

Mise à jour : Il y a 5 ans
Référence : EUCTR2015-003538-28

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

• Rate of Clinically Significant Asthma Exacerbations Per Patient in the 24-week Fixed-dose Steroid • Percentage of Participants With at Least 1 Adverse Event


Critère d'inclusion

  • Moderate-severe inadequately controlled Allergic Asthma